Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.

Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, Whitcher B, Clarke L, Plummer R, Judson I, Jones R, Alonzi R, Brunner T, Koh DM, Murphy P, Waterton JC, Parker G, Graves MJ, Scheenen TW, Redpath TW, Orton M, Karczmar G, Huisman H, Barentsz J, Padhani A; Experimental Cancer Medicine Centres Imaging Network Steering Committee.

Eur Radiol. 2012 Jul;22(7):1451-64. doi: 10.1007/s00330-012-2446-x. Epub 2012 May 7.

PMID:
22562143
[PubMed - indexed for MEDLINE]
2.

Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials.

Leen E, Averkiou M, Arditi M, Burns P, Bokor D, Gauthier T, Kono Y, Lucidarme O.

Eur Radiol. 2012 Jul;22(7):1442-50. doi: 10.1007/s00330-011-2373-2.

PMID:
22302501
[PubMed - indexed for MEDLINE]
3.

Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography.

Miles KA, Lee TY, Goh V, Klotz E, Cuenod C, Bisdas S, Groves AM, Hayball MP, Alonzi R, Brunner T; Experimental Cancer Medicine Centre Imaging Network Group.

Eur Radiol. 2012 Jul;22(7):1430-41. doi: 10.1007/s00330-012-2379-4. Epub 2012 Feb 26.

PMID:
22367468
[PubMed - indexed for MEDLINE]
4.

MR imaging of tumor microcirculation: promise for the new millennium.

Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, Mayr N.

J Magn Reson Imaging. 1999 Dec;10(6):903-7.

PMID:
10581502
[PubMed - indexed for MEDLINE]
5.

Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.

Rosen MA, Schnall MD.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):770s-776s. Review.

PMID:
17255308
[PubMed - indexed for MEDLINE]
Free Article
6.

Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, Sbarbati A, Osculati F.

Clin Cancer Res. 2005 Aug 15;11(16):5827-32.

PMID:
16115922
[PubMed - indexed for MEDLINE]
Free Article
7.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

PMID:
12869717
[PubMed - indexed for MEDLINE]
Free Article
8.

Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review.

Yang X, Knopp MV.

J Biomed Biotechnol. 2011;2011:732848. doi: 10.1155/2011/732848. Epub 2011 Apr 26. Review.

PMID:
21541193
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Dynamic contrast-enhanced MRI in oncology drug development.

Cheng HL.

Curr Clin Pharmacol. 2007 May;2(2):111-22. Review.

PMID:
18690858
[PubMed - indexed for MEDLINE]
10.

Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.

Choyke PL, Dwyer AJ, Knopp MV.

J Magn Reson Imaging. 2003 May;17(5):509-20. Review.

PMID:
12720260
[PubMed - indexed for MEDLINE]
11.

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM.

Magn Reson Imaging. 2007 Apr;25(3):319-27. Epub 2007 Feb 5.

PMID:
17371720
[PubMed - indexed for MEDLINE]
12.

Dynamic contrast-enhanced magnetic resonance imaging in oncology.

Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, Choyke P.

Top Magn Reson Imaging. 2001 Aug;12(4):301-8. Review.

PMID:
11687716
[PubMed - indexed for MEDLINE]
13.

Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis.

Atkin G, Taylor NJ, Daley FM, Stirling JJ, Richman P, Glynne-Jones R, d'Arcy JA, Collins DJ, Padhani AR.

Br J Surg. 2006 Aug;93(8):992-1000.

PMID:
16673354
[PubMed - indexed for MEDLINE]
14.

Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report.

Evelhoch J, Garwood M, Vigneron D, Knopp M, Sullivan D, Menkens A, Clarke L, Liu G.

Cancer Res. 2005 Aug 15;65(16):7041-4.

PMID:
16103049
[PubMed - indexed for MEDLINE]
Free Article
15.

Fundamentals of quantitative dynamic contrast-enhanced MR imaging.

Paldino MJ, Barboriak DP.

Magn Reson Imaging Clin N Am. 2009 May;17(2):277-89. doi: 10.1016/j.mric.2009.01.007. Review.

PMID:
19406359
[PubMed - indexed for MEDLINE]
16.

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

Jackson A, O'Connor JP, Parker GJ, Jayson GC.

Clin Cancer Res. 2007 Jun 15;13(12):3449-59. Review.

PMID:
17575207
[PubMed - indexed for MEDLINE]
Free Article
17.

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.

O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC.

Nat Rev Clin Oncol. 2012 Feb 14;9(3):167-77. doi: 10.1038/nrclinonc.2012.2. Review.

PMID:
22330689
[PubMed - indexed for MEDLINE]
18.

Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy.

Kim JH, Kim CK, Park BK, Park SY, Huh SJ, Kim B.

Eur Radiol. 2012 Nov;22(11):2533-9. doi: 10.1007/s00330-012-2504-4. Epub 2012 Jun 1.

PMID:
22653283
[PubMed - indexed for MEDLINE]
19.

Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements.

Brix G, Griebel J, Kiessling F, Wenz F.

Eur J Nucl Med Mol Imaging. 2010 Aug;37 Suppl 1:S30-51. doi: 10.1007/s00259-010-1448-7. Review.

PMID:
20503049
[PubMed - indexed for MEDLINE]
20.

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, Schnell C, Wood J.

NMR Biomed. 2005 Aug;18(5):308-21.

PMID:
15918178
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk